Criteria for Approval

1) Indications and Usage
   - Management of cystic fibrosis (CF) patients with *Pseudomonas aeruginosa*

2) Age greater than or equal to 6 years of age

Duration of Approval

- Up to twelve months

Quantity Limit

- 224 per 56 day cycle (28 days on, 28 days off)

Criteria for Denial

1) Age less than 6 years

2) Forced expiratory volume in 1 second (FEV₁) < 25% or > 80% predicted

3) Colonization with *Burkholderia cepacia*

4) Concurrent or alternating use of inhaled aztreonam

References

1. TOBI Podhaler [package insert]. East Hanover, NJ; Novartis, April 2014.
